Literature DB >> 28639073

Prognostic factors affecting outcomes in fistulating perianal Crohn's disease: a systematic review.

G C Braithwaite1, M J Lee2,3, D Hind4, S R Brown5,4.   

Abstract

BACKGROUND: One in three patients with Crohn's disease will develop a perianal fistulae, and one third of these will achieve long-term healing or closure. A barrier to conducting well-designed clinical trials for these patients is a lack of understanding of prognostic factors. This systematic review sets out to identify factors associated with prognosis of perianal Crohn's fistulae.
METHODS: This review was registered on the PROSPERO database (CRD42016050316) and conducted in line with PRISMA guidelines along a predefined protocol. English-language studies assessing baseline factors related to outcomes of fistulae treatment in adult patients were included. Searches were performed on MEDLINE and Embase databases. Screening of abstracts and full texts for eligibility was performed prior to extraction of data into predesigned forms. Bias was assessed using the QUIPS tool.
RESULTS: Searches identified 997 papers. Following removal of duplicates and secondary searches, 923 were screened for inclusion. Forty-seven papers were reviewed at full-text level and 13, 2 of which were randomised trials, were included in the final qualitative review. Two studies reported distribution of Crohn's disease as a prognostic factor for healing. Two studies found that CARD15 mutations decreased response of fistulae to antibiotics. Complexity of fistulae anatomy was implicated in prognosis by 4 studies.
CONCLUSIONS: This systematic review has identified potential prognostic markers, including genetic factors and disease behaviour. We cannot, however, draw robust conclusions from this heterogeneous group of studies; therefore, we recommend that a prospective cohort study of well-characterised patients with Crohn's perianal fistulae is undertaken.

Entities:  

Keywords:  Crohn’s disease; Perianal fistulae; Prognosis; Systematic review

Mesh:

Substances:

Year:  2017        PMID: 28639073      PMCID: PMC5550543          DOI: 10.1007/s10151-017-1647-3

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  56 in total

Review 1.  Is simple fistula-in-ano simple?

Authors:  Y P Sangwan; L Rosen; R D Riether; J J Stasik; J A Sheets; I T Khubchandani
Journal:  Dis Colon Rectum       Date:  1994-09       Impact factor: 4.585

2.  Impact of Smoking Cessation on the Clinical Course of Crohn's Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study.

Authors:  Tiago Nunes; Maria Josefina Etchevers; Valle García-Sánchez; Daniel Ginard; Eva Martí; Manuel Barreiro-de Acosta; Fernando Gomollón; Maite Arroyo; Guillermo Bastida; Benito Gonzalez; David Monfort; Esther García-Planella; Carolina Figueroa; Julián Panés; Miquel Sans
Journal:  Am J Gastroenterol       Date:  2016-02-09       Impact factor: 10.864

Review 3.  Pathophysiology of fistula formation in Crohn's disease.

Authors:  Michael Scharl; Gerhard Rogler
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

4.  The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn's disease.

Authors:  A Haennig; G Staumont; B Lepage; P Faure; L Alric; L Buscail; B Bournet; J Moreau
Journal:  Colorectal Dis       Date:  2015-04       Impact factor: 3.788

5.  Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.

Authors:  Floris Imhann; Arnau Vich Vila; Marc Jan Bonder; Jingyuan Fu; Dirk Gevers; Marijn C Visschedijk; Lieke M Spekhorst; Rudi Alberts; Lude Franke; Hendrik M van Dullemen; Rinze W F Ter Steege; Curtis Huttenhower; Gerard Dijkstra; Ramnik J Xavier; Eleonora A M Festen; Cisca Wijmenga; Alexandra Zhernakova; Rinse K Weersma
Journal:  Gut       Date:  2016-10-08       Impact factor: 23.059

6.  The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.

Authors:  S Lichtiger; D G Binion; D C Wolf; D H Present; A G Bensimon; E Wu; A P Yu; A T Cardoso; J Chao; P M Mulani; K G Lomax; J D Kent
Journal:  Aliment Pharmacol Ther       Date:  2010-09-28       Impact factor: 8.171

7.  Long-term success rate after surgical treatment of anorectal and rectovaginal fistulas in Crohn's disease.

Authors:  Thorsten Löffler; Thilo Welsch; Stefanie Mühl; Ulf Hinz; Jan Schmidt; Peter Kienle
Journal:  Int J Colorectal Dis       Date:  2009-01-27       Impact factor: 2.571

8.  Antimicrobial peptides in chronic anal fistula epithelium.

Authors:  Karlheinz Kiehne; Alexander Fincke; Gabriele Brunke; Tobias Lange; Ulrich R Fölsch; Karl-Heinz Herzig
Journal:  Scand J Gastroenterol       Date:  2007-09       Impact factor: 2.423

9.  Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group.

Authors:  E J Irvine
Journal:  J Clin Gastroenterol       Date:  1995-01       Impact factor: 3.062

10.  Use of a modified Delphi approach to develop research priorities for the association of coloproctology of Great Britain and Ireland.

Authors:  J Tiernan; A Cook; I Geh; B George; L Magill; J Northover; A Verjee; J Wheeler; N Fearnhead
Journal:  Colorectal Dis       Date:  2014-12       Impact factor: 3.788

View more
  2 in total

Review 1.  Management of anoperineal lesions in Crohn's disease: a French National Society of Coloproctology national consensus.

Authors:  D Bouchard; F Pigot; G Staumont; L Siproudhis; L Abramowitz; P Benfredj; C Brochard; N Fathallah; J-L Faucheron; T Higuero; Y Panis; V de Parades; B Vinson-Bonnet; D Laharie
Journal:  Tech Coloproctol       Date:  2019-01-02       Impact factor: 3.781

2.  Can visceral adipose tissue and skeletal muscle predict recurrence of newly diagnosed Crohn's disease in different treatments.

Authors:  Zinan Zhang; Xiaoyu Yu; Ning Fang; Xiuyan Long; Xixian Ruan; Jianing Qiu; Sifan Tao; Pan Gong; Kai Nie; An Li; Xiaoyan Wang; Li Tian
Journal:  BMC Gastroenterol       Date:  2022-05-18       Impact factor: 2.847

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.